Using FTIRS to detect and limit spread of ESBL-producing bacteria in ICUs
Impact of Fourier Transform Infrared Spectroscopy (FTIRS) on the Diffusion of ESBL Producing Enterobacterales in Intensive Care Units (ICU)
We will test whether a rapid FTIRS bacterial typing test for adult ICU patients who carry ESBL-producing Enterobacterales can reduce spread between patients.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 900 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | University Hospital, Caen Academic / other |
| Locations | 1 site (Caen) |
| Trial ID | NCT05872152 on ClinicalTrials.gov |
What this trial studies
Multidrug-resistant Enterobacterales, particularly ESBL-producing strains, pose a high risk of cross-transmission in intensive care units. This interventional study implements routine FTIRS typing of ESBL-E from rectal swabs to deliver rapid (about one hour) strain identification that can inform infection-control measures. FTIRS results will be used alongside standard culture workflows, recognizing whole genome sequencing (WGS/MLST/SNP) as the gold standard but less feasible for continuous surveillance. The study will compare cross-transmission rates before and after systematic FTIRS implementation to determine its impact on ESBL-E spread in the ICU.
Who should consider this trial
Good fit: Adults admitted to the participating ICU who are carriers of ESBL-producing Enterobacterales (identified by rectal swab) are the intended participants.
Not a fit: Patients who are not colonized with ESBL-producing bacteria or who are treated outside the participating ICU are unlikely to receive direct benefit from this intervention.
Why it matters
Potential benefit: If successful, routine FTIRS typing could reduce ICU spread of ESBL-producing bacteria and lower related infections and transmission events.
How similar studies have performed: FTIRS has shown promising rapid-typing accuracy in validation studies, but there is limited evidence from large clinical trials demonstrating reduced transmission compared with current practice or sequencing.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients hospitalized in ICU * ESBL-E carrier Exclusion Criteria: * none
Where this trial is running
Caen
- Chu Chen — Caen, France (Recruiting)
Study contacts
- Principal investigator: Camille Jeanne-Leroyer, PharmD — Caen Normandie Hospital
- Study coordinator: Camille Jeanne-Leroyer
- Email: jeanneleroyer-c@chu-caen.fr
- Phone: +33(0)231065947
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.